SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...
Artists take on election results blame game, a message for the billionaires, and more From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to ...
SAN FRANCISCO, November 03, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy ...
SAN FRANCISCO, October 22, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third ...
The Central Government has released a gazette notification listing gallantry award citations for defence personnel from multiple operations, including Operation Sindoor. The citations highlight acts ...
The latest price target for Vir Biotechnology (NASDAQ:VIR) was reported by HC Wainwright & Co. on September 15, 2025. The analyst firm set a price target for $15.00 expecting VIR to rise to within 12 ...
Marianne De Backer, PhD, MBA, CEO of Vir Biotechnology, has led the company's pivot to focusing on cancer as well as infectious diseases. [Vir Biotechnology] Between launching clinical studies for its ...
Hosted on MSN
Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation
Fintel reports that on July 11, 2025, Raymond James initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform recommendation. Analyst Price Forecast Suggests 232.11% Upside As of June ...
- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...
On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback